Účinnost lenalidomidu u vzácných krevních chorob: u histiocytózy z Langerhansových buněk, multicentrické Castlemanovy choroby, POEMS syndromu, Erdheimovy-Chesterovy choroby a angiomatózy. Popis případů a přehled literatury

• Title in English: The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis
• Authors: ADAM Zdeněk; POUR Luděk; KREJČÍ Marta; ZAHRADOVÁ Lenka; SZTURZ Petr; KOUKALOVÁ R.; ŘEHÁK Zdeněk; NEBESKÝ Tomáš; HÁJEK Roman; KRÁL Zdeněk; MAYER Jiří
• Year of publication: 2012
• Type: Article in Periodical
• Magazine / Source: Vnitřní lékařství
• MU Faculty or unit: Faculty of Medicine
• Field: Oncology and hematology
• Keywords: lenalidomide; thalidomide; cladribin; anakinra; Langerhans cell histiocytosis; Erdheim-Chester disease; Castleman disease; POEMS syndrome; angiomatosis

Attached files

• VL_2012-11_Adam.pdf

• Description: We observed an excellent effect of lenalidomide in multifocal aggressive, repeatedly relapsing Langerhans cell histiocytosis where it led to complete remission. We showed an effect of lenalidomide in Langerhans cell histiocytosis and in Castleman disease. The treatment led to regression of brain infiltrates in a patient with Erdheim-Chester disease. A dose of 10 mg of lenalidomide daily in combination with 50 mg of thalidomide stabilized a course of angiomatosis. Lenalidomide did not deliver the required treatment response in a patient with POEMS syndrome and multiple previous therapies.

Related projects

• From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies
• Úloha mitotické disrupce v B lymfocytech u mnohočetného myelomu
• Nové diagnostické a klinické přístupy v onkologii